Conatus Pharmaceuticals Inc., of San Diego, presented a late-breaking poster on rapid and statistically significant reduction of markers of apoptosis and cell death in subjects with mild, moderate and severe hepatic impairment treated with a single dose of its pan-caspase inhibitor, emricasan.